Cough Reduction in IPF With Nalbuphine ER (CORAL)
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: Trevi Therapeutics
Listed as NCT05964335, this PHASE2 trial focuses on Idiopathic Pulmonary Fibrosis and remains completed. Sponsored by Trevi Therapeutics, it has been updated 16 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Feb 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
▶ Show 11 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Trevi Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .